Georgia's Online Cancer Information Center

Find A Clinical Trial

ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies

Cancer Type
Hematopoietic Malignancies
Non-Hodgkin Lymphoma
Unknown Primary
Trial Phase
Phase I
18 Years and older, Male and Female
Study Type
Protocol IDs
ACE1831-001 (primary)
Study Sponsor
Acepodia Biotech, Inc.


ACE1831 is an off-the-shelf, allogeneic gamma delta T (gdT) cell therapy derived from
healthy donors, that is under investigation for the treatment of CD20-expressing B-cell

The ACE1831-001 study is an open-label, Phase I, first-in-human (FIH) study that aims to
evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics, and efficacy
of ACE1831 in patients with CD20-expressing Non-Hodgkin lymphoma.


  1. CD20-positive B-cell NHL that is persistent or progressive after having received at least 2 prior systemic therapies per NCCN guidelines
  2. At least 1 measurable lesion according to the revised International Working Group (IWG) Response Criteria for Malignant Lymphoma
  3. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1
  4. Adequate hematologic and renal, hepatic, and cardiac function
  5. Oxygen saturation via pulse oxygenation = 92% at rest on room air Key

Treatment Sites in Georgia

Winship Cancer Institute of Emory University

1365 Clifton Road NE
Building C
Atlanta, GA 30322

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.